Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;65(3):301-311.
doi: 10.1080/10428194.2023.2287965. Epub 2023 Dec 13.

Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas

Zachary Braunstein  1 , Allyson Waller  2 , Emily Dotson  2 , Eric McLaughlin  3 , Walter Hanel  4 , John Reneau  4 , Daniel Addison  5 , Pierluigi Porcu  6 , Jonathan Edward Brammer  4
Affiliations

Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas

Zachary Braunstein et al. Leuk Lymphoma. 2024 Mar.

Abstract

Aggressive T-cell lymphomas (TCL) account for 10-15% of non-Hodgkin lymphomas (NHL) with weaker responses and shorter durations to chemotherapy than other types of NHL. Current therapies for patients with relapsed/refractory Cutaneous T-cell lymphoma (CTCL) have limited efficacy, and short durations of response. Gemcitabine and liposomal doxorubicin have shown single-agent activity in TCL and combined have activity in relapsed B-cell lymphomas. We evaluated outcomes of 18 patients with relapsed/refractory aggressive TCL (13 CTCL, 5 PTCL) treated with a gemcitabine plus liposomal doxorubicin (GemDox) combination and evaluated outcomes with a specific focus on CTCL patients. Significant responses were observed in CTCL patients with an overall response rate of over 80%. In all patients, objective responses were seen in eight patients (50%), with six patients (5 CTCL) able to proceed to allogeneic stem cell transplant. Given limited treatment options for r/r CTCL, GemDox should be considered a therapeutic option in relapsed/refractory CTCL.

Keywords: Chemotherapeutic approaches; lymphoma and Hodgkin disease; pharmacotherapeutics.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement

No potential conflict of interests was reported by the authors.

Figures

Figure 1.
Figure 1.
Kaplan–Meier curve of full cohort OS and PFS.
Figure 2.
Figure 2.
Kaplan–Meier curve of CTCL OS and PFS.
See this image and copyright information in PMC

References

    1. Horwitz SM, Ansell S, Ai WZ, et al. T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(3):285–308. doi: 10.6004/jnccn.2022.0015 - DOI - PubMed
    1. Khan N, Noor SJ, Horwitz S. How we treat mycosis fungoides and sézary syndrome. Clin Adv Hematol Oncol. 2021;19(9):573–581. - PMC - PubMed
    1. Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098–5106. doi: 10.1182/bloodadvances.2021004710 - DOI - PMC - PubMed
    1. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631–636. doi: 10.1200/JCO.2011.37.4223 - DOI - PubMed
    1. Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7(1):11. doi: 10.1186/1756-8722-7-11 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources